Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Inflammatory Bowel Disease (IBD) Fellowship- United StatesRelease Date:Fellowship Inflammation & Immunology USA Title Grant Type Focus Area Country Application Due Date Updates in RSV Prevention for Prenatal Care Workers Serving Marginalized CommunitiesRelease Date:Education Vaccines USA Acquired Aplastic Anemia: Educational programs to upskill hematologists & primary care physicians with current best practicesRelease Date:Education Hospital All Bridging the Inflammatory Dermatosis Care Divide with TeledermatologyRelease Date:Partner: The George Washington UniversityQuality Improvement Inflammation & Immunology USA Knowledge Gaps in Drug-Drug Interactions in COVID-19 Outpatient TreatmentRelease Date:Education Vaccines USA Optimizing COVID-19 Treatment Strategies in Elderly Vulnerable Populations in CanadaRelease Date:Quality Improvement Vaccines Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in CanadaRelease Date:Research Rare Disease Canada Improving access to and the quality of clinical diagnostic solutions (Africa Geographic Scope)Release Date:Quality Improvement Support for the Professions All Patient Education and Support for the Management of MigraineRelease Date:Education Internal Medicine All Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism (ex-US)Education Internal Medicine All Raising Awareness and Promoting Timely Diagnosis of TTR AmyloidosisRelease Date:Partner: Global Bridges at Mayo ClinicQuality Improvement Rare Disease All Accord for a Healthier World: Antimicrobial Resistance Testing & Stewardship to Improve Hospitalized Patients’ Health OutcomesRelease Date:Quality Improvement Hospital Malawi, Rwanda, Senegal Updates in Post-COVID Conditions: Potential Causes, Assessment, Testing, Management, and Ongoing ResearchRelease Date:Education Vaccines USA